NTLA vs. ACAD, MRUS, SWTX, RNA, ACLX, RARE, PTGX, AAPG, SRRK, and MTSR
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include ACADIA Pharmaceuticals (ACAD), Merus (MRUS), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.
Intellia Therapeutics vs. Its Competitors
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.
ACADIA Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals presently has a consensus target price of $27.88, suggesting a potential upside of 30.50%. Intellia Therapeutics has a consensus target price of $33.37, suggesting a potential upside of 237.74%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than ACADIA Pharmaceuticals.
In the previous week, ACADIA Pharmaceuticals had 19 more articles in the media than Intellia Therapeutics. MarketBeat recorded 24 mentions for ACADIA Pharmaceuticals and 5 mentions for Intellia Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.65 beat Intellia Therapeutics' score of 0.60 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.
ACADIA Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.
ACADIA Pharmaceuticals has a net margin of 22.97% compared to Intellia Therapeutics' net margin of -1,154.10%. ACADIA Pharmaceuticals' return on equity of 17.46% beat Intellia Therapeutics' return on equity.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
ACADIA Pharmaceuticals beats Intellia Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NTLA) was last updated on 7/1/2025 by MarketBeat.com Staff
Free NTLA Stock Alerts